News

Find out more about us and our portfolio companies

All years

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2025/10/14
Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025

THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stromal rich tumours.
UK clinical trial recruitment is on track, and additional international clinical sites are set to open for OCTOPOD-IV.
US trial (OCTOPOD-IP) utilising intraperitoneal delivery has been initiated.
2025/09/30
REPRONOVO ANNOUNCES CLINICAL TRIAL APPROVAL NOTICE FOR RPN-001 IN CHINA

The approval enables initiation of RPN-001 Phase 1 trial in China.
Key regulatory milestone in the global development of RPN‑001.

2025/10/14
Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025
2025/09/30
REPRONOVO ANNOUNCES CLINICAL TRIAL APPROVAL NOTICE FOR RPN-001 IN CHINA
2025/09/24
Artios Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC)
2025/09/22
TRIMTECH Therapeutics named as one of Fierce Biotech’s ‘Fierce 15’ for 2025
2025/09/08
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
2025/08/19
Polaris Announces Series A Funding Led by Koch Disruptive Technologies and Appoints Industry Veteran Morten Nissov as CEO to Accelerate Growth
2025/07/09
Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
2025/07/01
ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility
2025/07/01
NTT DATA and Corvic AI Partner on GenAI Value Drivers
2025/06/06
M Ventures Announces Key Leadership Changes in Technology Investment Team
2025/05/21
ReproNovo raises $65 Million Series A Financing to advance phase 2 clinical trials of novel therapies in reproductive medicine and Womens's Health
2025/05/01
Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs
2025/04/24
M Ventures co-leads $18.7M Series A investment in ChEmpower
2025/04/15
Corvic AI Raises $12M in Seed Funding to Pioneer AI Cognitive Infrastructure for Enterprise Intelligence
2025/03/25
Vizgen Announces New Appointments to Board of Directors and Executive Leadership Team
2025/03/12
Celestial AI Secures $250 Million Funding to Revolutionize AI Infrastructure with Its Photonic Fabric
2025/03/05
TRIMTECH Therapeutics raises $31M to advance targeted protein degradation for treatment of neurodegenerative diseases
2025/01/29
Concerto Biosciences Announces Appointment of Dr. Stewart Campbell to Board of Directors
2025/01/21
NovoLINC Secures Investments to Assist AI Computing with Groundbreaking Thermal Interface Technology
2025/01/16
Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer
2025/01/14
Tignis has been acquired by Cohu to Enhance Data Analytics and AI/ML Platform
2025/01/13
Ribometrix Strengthens Leadership by appointing William S. Marshall as CEO and Katie Warner as CSO

Find out more about us and our portfolio companies

Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025

REPRONOVO ANNOUNCES CLINICAL TRIAL APPROVAL NOTICE FOR RPN-001 IN CHINA

Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025

REPRONOVO ANNOUNCES CLINICAL TRIAL APPROVAL NOTICE FOR RPN-001 IN CHINA

Artios Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC)

TRIMTECH Therapeutics named as one of Fierce Biotech’s ‘Fierce 15’ for 2025

NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND

Polaris Announces Series A Funding Led by Koch Disruptive Technologies and Appoints Industry Veteran Morten Nissov as CEO to Accelerate Growth

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility

NTT DATA and Corvic AI Partner on GenAI Value Drivers

M Ventures Announces Key Leadership Changes in Technology Investment Team

ReproNovo raises $65 Million Series A Financing to advance phase 2 clinical trials of novel therapies in reproductive medicine and Womens's Health

Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs

M Ventures co-leads $18.7M Series A investment in ChEmpower

Corvic AI Raises $12M in Seed Funding to Pioneer AI Cognitive Infrastructure for Enterprise Intelligence

Vizgen Announces New Appointments to Board of Directors and Executive Leadership Team

Celestial AI Secures $250 Million Funding to Revolutionize AI Infrastructure with Its Photonic Fabric

TRIMTECH Therapeutics raises $31M to advance targeted protein degradation for treatment of neurodegenerative diseases

Concerto Biosciences Announces Appointment of Dr. Stewart Campbell to Board of Directors

NovoLINC Secures Investments to Assist AI Computing with Groundbreaking Thermal Interface Technology

Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer

Tignis has been acquired by Cohu to Enhance Data Analytics and AI/ML Platform

Ribometrix Strengthens Leadership by appointing William S. Marshall as CEO and Katie Warner as CSO